Skip to main content

Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

Clinical Trials Using Decitabine and Cedazuridine

Review the clinical trials studying decitabine and cedazuridine on this list and use the filters to refine the results by age and location. Some clinical trials are held at NCI-Designated Cancer Centers and may be supported by other organizations.

You can find more information about the types and phases of clinical trials and what to expect or use our Steps to Find a Clinical Trial.

Trials 1-25 of 28

Testing the Addition of an IDH2 Inhibitor, Enasidenib, to Usual Treatment (Cedazuridine-Decitabine) for Higher-Risk Myelodysplastic Syndrome (MDS) with IDH2 Mutation (A MyeloMATCH Treatment Trial)
Status: Active
Location: 104 locations
Testing the Addition of an Anti-cancer Drug, ASTX727 (Cedazuridine, Decitabine), to Chemotherapy (Paclitaxel) and Immunotherapy (Pembrolizumab) for Metastatic Triple-Negative Breast Cancer
Status: Active
Location: 9 locations
Testing the Combination of Nivolumab and ASTX727 for Relapsed or Refractory B-Cell Lymphoma
Status: Active
Location: 9 locations
ASTX727 for the Treatment of Malignant Nerve Sheath Tumors with PRC2 Mutation Loss
Status: Active
Location: 7 locations
A Randomized Study of ASTX727 with or without Iadademstat in Advanced Myeloproliferative Neoplasms (MPNs)
Status: Active
Location: 6 locations
Testing the Anti-cancer Drug, Cirtuvivint, and its Combination with ASTX727 to Improve Outcomes in Patients with Acute Myeloid Leukemia and Myelodysplastic Syndromes
Status: Active
Location: 5 locations
Active Myeloid Target Compound Decitabine and Cedazuridine in Combination with Itacitinib for the Treatment of Myelodysplastic/Myeloproliferative Neoplasm (MDS/MPN) Overlap Syndromes, ABNL-MARRO Study
Status: Active
Location: 4 locations
Decitabine and Cedazuridine for Early Treatment of High-Risk Clonal Cytopenia of Undetermined Significance
Status: Active
Location: 4 locations
ASTX727 for the Treatment of Advanced, Unresectable, or Metastatic Solid Tumors
Status: Active
Location: 2 locations
ASTX727 and Dasatinib for the Treatment of Newly Diagnosed Philadelphia Chromosome or BCR-ABL Positive Chronic Myeloid Leukemia in Chronic Phase
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Decitabine and Cedazuridine in Combination with Venetoclax for the Treatment of Patients who have Relapsed Acute Myeloid Leukemia after Donor Stem Cell Transplant
Status: Active
Location: Vanderbilt University/Ingram Cancer Center, Nashville, Tennessee
Olutasidenib in Combination with Hypomethylation Therapy for the Treatment of IDH1-Mutated Higher-Risk Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, and Myeloproliferative Neoplasms
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
SNDX-5613 with Decitabine/Cedazuridine, and Venetoclax for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia, SAVE Trial
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Decitabine/Cedazuridine and Venetoclax in Combination with Ivosidenib or Enasidenib for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Decitabine and Cedazuridine for the Improvement of Outcomes in Myelodysplastic Syndrome Patients with Measurable Residual Disease after Donor Stem Cell Transplantation
Status: Active
Location: Siteman Cancer Center at Washington University, Saint Louis, Missouri
ASTX727, Venetoclax, and Gilteritinib for the Treatment of Newly Diagnosed, Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Decitabine Alone or in Combination with Venetoclax, Gilteritinib, Enasidenib, or Ivosidenib as Maintenance Therapy for the Treatment of Acute Myeloid Leukemia in Remission
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Venetoclax in Combination with ASTX727 for the Treatment of Pediatric Patients with Relapsed or Refractory Acute Myeloid Leukemia
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Testing the Combination of Targeted Radiotherapy with Anti-Cancer Drugs, Venetoclax and ASTX-727, to Improve Outcomes for Adults with Newly Diagnosed Acute Myeloid Leukemia
Status: Active
Location: Yale University Cancer Center LAO, New Haven, Connecticut
Avapritinib in Combination with Decitabine for the Treatment of Patients with Systemic Mastocytosis with an Associated Hematologic Neoplasm
Status: Active
Location: Moffitt Cancer Center, Tampa, Florida
A Study for Participants Who Participated in Prior Clinical Studies of ASTX727 (Standard Dose)
Status: Enrolling by Invitation
Location: 2 locations
Decitabine/Cedazuridine (INQOVI), an Oral DNA Demethylating Agent, in Subjects With BAP1 Cancer Predisposition Syndrome and Subclinical, Early-Stage Mesothelioma
Status: Temporarily Closed to Accrual
Location: National Institutes of Health Clinical Center, Bethesda, Maryland
Venetoclax in Combination with ASTX727 for the Treatment of Chronic Myelomonocytic Leukemia and Other Myelodysplastic Syndrome/Myeloproliferative Neoplasm
Status: Temporarily Closed to Accrual
Location: 33 locations
Comparing New Treatments for People with Newly Diagnosed Acute Myeloid Leukemia That Has an IDH2 Gene Change (A MyeloMATCH Treatment Trial)
Status: Temporarily Closed to Accrual
Location: 86 locations
ASTX727 for the Treatment of IDH Mutant Recurrent Glioma
Status: Temporarily Closed to Accrual
Location: 3 locations